Jeremiah Deneve, DO, FACS
Dr. Jeremiah “Jig” Deneve is a surgical oncologist at UNC Health and the Lineberger Comprehensive Cancer Center. He specializes in complex surgery for peritoneal surface malignancies, Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy, Colorectal Cancer, Appendiceal Cancer, and Melanoma. He is an Associate Professor in the Division of Surgical Oncology at UNC School of Medicine and Program Director of the school’s Surgical Oncology Fellowship.[1]
Dr. Deneve has experience with establishing programs dedicated to the treatment of Peritoneal Surface Malignancies including malignant peritoneal mesothelioma, and plans on helping to establish a program at UNC Health and the Lineberger Comprehensive Cancer Center. He takes great pleasure in working on a multidisciplinary team of physicians working to provide comprehensive treatment and enjoys the challenge and opportunity to help provide the best possible outcome for his patients.[2]
Education and Career
Dr. Deneve began his education by earning a bachelor of science degree at Auburn University of Montgomery. From there he went on to earn his Doctor of Osteopathic Medicine degree at the Chicago College of Osteopathic Medicine of Midwestern University. He completed his internship and residency at Emory University School of Medicine and fellowships in both Surgical Oncology at Moffitt Cancer Center at the University of South Florida and a Cardiothoracic Research Fellowship at Emory University School of Medicine.[1]
Before assuming his role at UNC Lineberger Comprehensive Cancer Center, Dr. Deneve practiced at the University of Tennessee Health Science Center in Memphis, Tennessee, and was also affiliated with the Memphis Veterans Affairs Medical Center. He joined UNC to provide complex surgical oncology care to patients diagnosed with challenging cancers and to help establish a Peritoneal Surface Malignancy program.[2]
Research
Dr. Deneve is an active researcher who has co-authored and contributed to numerous publications and articles that have appeared in professional journals. These include:
Management of malignant bowel obstruction – Authors’ reply.Lancet Gastroenterol Hepatol. 2024 Jan;9(1):15. doi: 10.1016/S2468-1253(23)00367-9.PMID: 38070516 No abstract available.
ASO Visual Abstract: Malignant Solid Pseudopapillary Neoplasm of the Pancreas-An Orthogonal Analysis. Ann Surg Oncol. 2023 Nov 14. doi: 10.1245/s10434-023-14542-9. Online ahead of print.PMID: 37962743 No abstract available.
Malignant Solid Pseudopapillary Neoplasm of the Pancreas: An Orthogonal Analysis.
Ann Surg Oncol. 2024 Jan;31(1):475-487. doi: 10.1245/s10434-023-14343-0. Epub 2023 Sep 28.PMID: 37768414
Nationwide analysis of unplanned conversion during minimally invasive distal pancreatectomy for pancreatic adenocarcinoma. HPB (Oxford). 2023 Dec;25(12):1566-1572. doi: 10.1016/j.hpb.2023.08.009. Epub 2023 Aug 22.PMID: 37652810
Lymph node metastases in young patients with gastrointestinal stromal tumor: A nationwide analysis. J Surg Oncol. 2023 Dec;128(8):1268-1277. doi: 10.1002/jso.27431. Epub 2023 Aug 31.PMID: 37650827
Surgical versus non-surgical management for patients with malignant bowel obstruction (S1316): a pragmatic comparative effectiveness trial. Lancet Gastroenterol Hepatol. 2023 Oct;8(10):908-918. doi: 10.1016/S2468-1253(23)00191-7. Epub 2023 Aug 1.PMID: 37541263 Clinical Trial.
